Group 1 - The core viewpoint of the news is that Enhua Pharmaceutical has seen a stock price increase of 5.16%, reaching 27.52 CNY per share, with a total market capitalization of 27.954 billion CNY [1] - Enhua Pharmaceutical, established on March 29, 1999, and listed on July 23, 2008, is primarily engaged in the production, research, and sales of pharmaceuticals, with a revenue composition that includes 54.28% from anesthetics, 20.63% from psychotropic drugs, and 13.08% from commercial pharmaceuticals [1] - The trading volume for Enhua Pharmaceutical was 243 million CNY, with a turnover rate of 1.02% [1] Group 2 - The Guoshou Anbao Health Science Mixed A Fund (005043) holds 140,000 shares of Enhua Pharmaceutical, unchanged from the previous period, representing 5.72% of the fund's net value [2] - The fund has generated a floating profit of approximately 189,000 CNY as of the report date [2] - The fund was established on November 1, 2017, with a current scale of 5.0782 million CNY and has achieved a year-to-date return of 5.38% [2] Group 3 - The fund manager of Guoshou Anbao Health Science Mixed A is Wang Xueying, who has been in the position for 1 year and 183 days [3] - The total asset size of the fund is 50.8314 million CNY, with the best and worst fund returns during Wang's tenure being -1.18% and -1.62%, respectively [3]